ArticleIntensive care medicine experimental2025
Timing of inotropic support is associated with mortality in patients with acute decompensated heart failure-associated cardiogenic shock.
Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organ Support Requirements as Markers of Disease Severity and Mortality in Hospitalized Patients.Journal of clinical medicine · 2026Article
- Endothelial Activation and Stress Index (EASIX) Predicts In-Hospital Mortality in Acute Decompensated Heart Failure with Reduced Ejection Fraction.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInotropic support is often used to improve hemodynamics and organ perfusion in patients with advanced heart failure-related cardiogenic shock (ADHF-CS). We aimed to evaluate the effect of inotrope timing on patient mortality in patients meeting Society for Cardiovascular Angiography and Interventions (SCAI) stage-C criteria within 24 h of hospital presentation.
methodsWe analyzed a local cardiogenic shock database of patients admitted to our cardiovascular intensive care units at the University of Pennsylvania from five emergency departments between 2021 and 2023. Adult patients with left ventricular ejection fraction ≤40% were eligible for inclusion. Patients with hypoperfusion, who met at least one physical, biochemical, and hemodynamic criterion for SCAI-C shock were included. The primary outcome was 28-day mortality. We also compared SCAI criteria and diagnostic examination timing between early and delayed inotropic support groups.
resultsA total of 138 out of 623 patients (22%) with cardiogenic shock met inclusion criteria for this study. 28-day mortality was higher in patients who received inotropic therapies ≥8 h after cardiogenic shock onset compared to patients who received earlier support (4-h odds ratio of death (OR) 3.19, 95% CI: 1.34-8.03; 8-h OR: 2.4, 95% CI: 1.09-5.26). 28-day mortality was lower in the early inotrope group (<8 h from shock onset) compared to the delayed (≥8 h) group (15/87; 17% vs. 17/51; 32%, p = 0.031). Patients with early inotropic support more often presented with a cool peripheral exam (34% vs. 16%, p = 0.022) and an initial lactate > 2 mmol/dL (71% vs. 49%, p = 0.009). Delayed inotropic support was associated with hypotension at presentation (84% vs. 57%, p = 0.001), longer time to echocardiography (19 [11-36] vs. 15 [3-24] h, p = 0.053) and time to pulmonary artery catheterization (25 [16-45] vs. 16 [2-46] h, p = 0.042).
conclusionOur findings suggest that inotropic support initiated within 8 h of acute presentation is associated with decreased 28-day mortality for patients with ADHF-related cardiogenic shock. Peripheral perfusion and cardiac output measurement were less frequently quantified within the first 24 h for patients with delayed inotropic support. Using shock classification tools, such as the SCAI shock criteria, may help identify patients with CS, especially in its early stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.